Content
China Biopharma Out-Licensing Surges to Record $137.7B in 2025, 2026 on Pace to Break It Again
Cross-border licensing deals between Greater China-based biopharmaceutical companies and global drugmakers reached an unprecedented $137.7 billion in 2025, a nearly tenfold increase from 2021’s $13.9 billion, according to China-based data provider PharmCube. Industry analysts now predict 2026 will surpass that
20 February 2026